尼可地尔联合替格瑞洛对冠心病PCI术后患者血清酶抗氧化指标、MPO及Hcy水平的影响  

Effects of nicorandil combined with ticagrelor on serum enzyme antioxidant indexes,MPO and Hcy levels in patients with coronary heart disease after PCI

作　　者：王霞[1] 李亚洁[1] WANG Xia;LI Yajie(Cardiovascular Internal Medicine Department,Baoji Central Hospital,Baoji 721008,China)

机构地区：[1]宝鸡市中心医院心血管内科,陕西宝鸡721008

出　　处：《临床医学研究与实践》2023年第20期17-20,共4页Clinical Research and Practice

摘　　要：目的探讨尼可地尔联合替格瑞洛对冠心病经皮冠状动脉介入治疗(PCI)术后患者血清酶抗氧化指标、髓过氧化物酶(MPO)及同型半胱氨酸(Hcy)水平的影响。方法选取2020年7月至2021年6月我院收治的104例冠心病患者,均接受PCI手术治疗,按照随机数字表法将其分为观察组(52例,尼可地尔联合替格瑞洛治疗)和对照组(52例,替格瑞洛治疗)。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,观察组的左心室射血分数(LVEF)、每搏输出量(SV)、超氧化物歧化酶(SOD)、总抗氧化能力(TAC)及过氧化氢酶(CAT)水平高于对照组,左心室舒张末期内径(LVEDD)、MPO及Hcy水平低于对照组(P<0.05)。两组治疗期间的心血管不良事件总发生率无显著差异(P>0.05)。结论尼可地尔联合替格瑞洛在冠心病PCI术后患者中的应用效果显著,可提高机体血清酶抗氧化指标,改善MPO及Hcy水平。Objective To investigate the effects of nicorandil combined with ticagrelor on serum enzyme antioxidant indexes,myeloperoxidase(MPO)and homocysteine(Hcy)levels in patients with coronary heart disease after percutaneous coronary intervention(PCI).Methods A total of 104 patients with coronary heart disease admitted in our hospital from July 2020 to June 2021 were selected,and all of them received PCI surgery.According to the random number table method,the patients were divided into observation group(52 cases,nicorandil combined with ticagrelor treatment)and control group(52 cases,ticagrelor treatment).The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF),stroke volume(SV),superoxide dismutase(SOD),total antioxidant capacity(TAC)and catalase(CAT)levels in the observation group were higher than those in the control group,and the left ventricular end-diastolic dimension(LVEDD),MPO and Hcy levels were lower than those in the control group(P<0.05).There was no significant difference in the total incidence of cardiovascular adverse events between the two groups during the treatment period(P>0.05).Conclusion Nicorandil combined with ticagrelor applied in patients with coronary heart disease after PCI has a significant effect,which can improve the body's serum enzyme antioxidant indexes,and ameliorate MPO and Hcy levels.

关 键 词：尼可地尔 替格瑞洛 冠心病 经皮冠状动脉介入治疗 心功能 

分 类 号：R541.4[医药卫生—心血管疾病]